Diligence memo · auto-generated · as of July 2, 2026
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Recursion Pharmaceuticals, Inc. operates in Pharmaceuticals, based in SALT LAKE CITY. Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today!
Sub-sector tags: ai/ml, pharma.
Capital & rounds (filed)filed
Recursion Pharmaceuticals, Inc. has raised $478M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $246M on 2020-09-01.
Most recent recorded round closed around 2020-09-01.
Valuation (modeled)modeled
Provath models Recursion Pharmaceuticals, Inc. at approximately $8.3B (range $1.2B–$17.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.23× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 5.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Nuvation Bio Inc., Vyripharm Enterprises, Inc., Verona Pharma plc, Cingulate Inc., Day One Biopharmaceuticals Holding Co LLC.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.